102 related articles for article (PubMed ID: 35711654)
21. Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV.
Orkin C; Cahn P; Castagna A; Emu B; Harrigan PR; Kuritzkes DR; Nelson M; Schapiro J
HIV Med; 2022 Oct; 23(9):936-946. PubMed ID: 35293094
[TBL] [Abstract][Full Text] [Related]
22. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide.
Xue J; Chong H; Zhu Y; Zhang J; Tong L; Lu J; Chen T; Cong Z; Wei Q; He Y
Cell; 2022 Jan; 185(1):131-144.e18. PubMed ID: 34919814
[TBL] [Abstract][Full Text] [Related]
23. Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021.
Deeks SG; Archin N; Cannon P; Collins S; Jones RB; de Jong MAWP; Lambotte O; Lamplough R; Ndung'u T; Sugarman J; Tiemessen CT; Vandekerckhove L; Lewin SR;
Nat Med; 2021 Dec; 27(12):2085-2098. PubMed ID: 34848888
[TBL] [Abstract][Full Text] [Related]
24. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.
Chen Y; Jin H; Tang X; Li L; Geng X; Zhu Y; Chong H; He Y
Emerg Microbes Infect; 2022 Dec; 11(1):30-49. PubMed ID: 34821542
[TBL] [Abstract][Full Text] [Related]
25. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
Li S; Qiao Y; Jiang S; Wang B; Kong W; Shan Y
J Control Release; 2021 Oct; 338():633-643. PubMed ID: 34509584
[TBL] [Abstract][Full Text] [Related]
26. Safety Assessment of Microbicide 2P23 on the Rectal and Vaginal Microbiota and Its Antiviral Activity on HIV Infection.
Gao Z; Fu R; Li X; Wang J; He Y
Front Immunol; 2021; 12():702172. PubMed ID: 34447373
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
28. Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.
Rossignol E; Alter G; Julg B
J Infect Dis; 2021 Feb; 223(12 Suppl 2):22-31. PubMed ID: 33586772
[TBL] [Abstract][Full Text] [Related]
29. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy.
Jin H; Tang X; Li L; Chen Y; Zhu Y; Chong H; He Y
Cell Mol Immunol; 2021 Mar; 18(3):660-674. PubMed ID: 33462383
[TBL] [Abstract][Full Text] [Related]
30. Efficacy, Pharmacokinetics, and Safety Over 48 Weeks With Ibalizumab-Based Therapy in Treatment-Experienced Adults Infected With HIV-1: A Phase 2a Study.
Gathe JC; Hardwicke RL; Garcia F; Weinheimer S; Lewis ST; Cash RB
J Acquir Immune Defic Syndr; 2021 Apr; 86(4):482-489. PubMed ID: 33427765
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study.
Su B; Yao C; Zhao QX; Cai WP; Wang M; Lu HZ; Chen YY; Liu L; Wang H; He Y; Zheng YH; Li LH; Chen JF; Yu JH; Zhu B; Zhao M; Sun YT; Lun WH; Xia W; Sun LJ; Dai LL; Jiang TY; Wang MX; Zheng QS; Peng HY; Wang Y; Lu RJ; Hu JH; Xing H; Shao YM; Xie D; Zhang T; Zhang FJ; Wu H;
Chin Med J (Engl); 2020 Nov; 133(24):2919-2927. PubMed ID: 33252379
[TBL] [Abstract][Full Text] [Related]
32. Engineering antibody-based molecules for HIV treatment and cure.
Tuyishime M; Ferrari G
Curr Opin HIV AIDS; 2020 Sep; 15(5):290-299. PubMed ID: 32732551
[TBL] [Abstract][Full Text] [Related]
33. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
[TBL] [Abstract][Full Text] [Related]
34. Neutralization Breadth and Potency of Single-Chain Variable Fragments Derived from Broadly Neutralizing Antibodies Targeting Multiple Epitopes on the HIV-1 Envelope.
van Dorsten RT; Lambson BE; Wibmer CK; Weinberg MS; Moore PL; Morris L
J Virol; 2020 Jan; 94(2):. PubMed ID: 31619559
[TBL] [Abstract][Full Text] [Related]
35. A Membrane-Anchored Short-Peptide Fusion Inhibitor Fully Protects Target Cells from Infections of Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Tang X; Jin H; Chen Y; Li L; Zhu Y; Chong H; He Y
J Virol; 2019 Nov; 93(22):. PubMed ID: 31462566
[TBL] [Abstract][Full Text] [Related]
36. The Impact of HIV-1 Drug Escape on the Global Treatment Landscape.
Collier DA; Monit C; Gupta RK
Cell Host Microbe; 2019 Jul; 26(1):48-60. PubMed ID: 31295424
[TBL] [Abstract][Full Text] [Related]
37. Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.
Zhu Y; Chong H; Yu D; Guo Y; Zhou Y; He Y
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867304
[TBL] [Abstract][Full Text] [Related]
38. Recent progress in broadly neutralizing antibodies to HIV.
Sok D; Burton DR
Nat Immunol; 2018 Nov; 19(11):1179-1188. PubMed ID: 30333615
[TBL] [Abstract][Full Text] [Related]
39. Engineering multi-specific antibodies against HIV-1.
Padte NN; Yu J; Huang Y; Ho DD
Retrovirology; 2018 Aug; 15(1):60. PubMed ID: 30157871
[TBL] [Abstract][Full Text] [Related]
40. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B; Fessel J; Schrader S; Kumar P; Richmond G; Win S; Weinheimer S; Marsolais C; Lewis S
N Engl J Med; 2018 Aug; 379(7):645-654. PubMed ID: 30110589
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
